# Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

> **NCT03532737** · PHASE2 · UNKNOWN · sponsor: **Kuwait Cancer Control Center** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03532737
- **Lead sponsor:** Kuwait Cancer Control Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-07
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-10-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532737, "Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03532737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*